Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis.
暂无分享,去创建一个
Oded Gonen | Brian J Soher | R. Grossman | O. Gonen | L. J. Mannon | B. Soher | B. S. Li | Belinda S Y Li | Robert I Grossman | Lois J Mannon | Juleiga Regal | J. Regal
[1] F. Barkhof,et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.
[2] C. Lucchinetti,et al. Remyelination in multiple sclerosis , 1997, Multiple sclerosis.
[3] F Barkhof,et al. Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.
[4] R I Grossman,et al. Perspectives on multiple sclerosis. , 1998, AJNR. American journal of neuroradiology.
[5] J S Taylor,et al. Chemical shift imaging of human brain: axial, sagittal, and coronal P-31 metabolite images. , 1990, Radiology.
[6] D. Gadian,et al. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[7] G. Barker,et al. Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations , 2000, Journal of neurology, neurosurgery, and psychiatry.
[8] F. Barkhof,et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. , 1998, AJNR. American journal of neuroradiology.
[9] P. Matthews,et al. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. , 1998, Journal of neurology, neurosurgery, and psychiatry.
[10] H. Larsson,et al. The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. , 1993, Magnetic resonance imaging.
[11] F Barkhof,et al. The role of MRI as a surrogate outcome measure in multiple sclerosis , 2002, Multiple sclerosis.
[12] J K Udupa,et al. Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images--lack of correlation between changes in T2 lesion volume and clinical findings. , 1999, Radiology.
[13] Alan J. Thompson,et al. Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR , 2002, Journal of Neurology.
[14] Oded Gonen,et al. Reproducibility of 3D proton spectroscopy in the human brain , 2002, Magnetic resonance in medicine.
[15] F. Barkhof,et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.
[16] H. Tobi,et al. Correlating MRI and clinical disease activity in multiple sclerosis , 1995, Neurology.
[17] J. Duyn,et al. Quantitative proton MR spectroscopic imaging of the human brain , 1996, Magnetic resonance in medicine.
[18] F Barkhof,et al. T1 hypointensities and axonal loss. , 2000, Neuroimaging clinics of North America.
[19] W Steinbrich,et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. , 2000, AJNR. American journal of neuroradiology.
[20] B. Weinshenker,et al. Natural history of multiple sclerosis. , 2005, Neurologic clinics.
[21] G J Barker,et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.
[22] M Cercignani,et al. Diffusion tensor magnetic resonance imaging in multiple sclerosis , 2001, Neurology.
[23] R Stoyanova,et al. 3D multivoxel proton spectroscopy of human brain using a hybrid of 8th‐order hadamard encoding with 2D chemical shift imaging , 1998, Magnetic resonance in medicine.
[24] J. Cumings,et al. Biochemistry and the Central Nervous System , 1967, Neurology.
[25] J. Simon. Contrast‐enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis , 1997, Journal of magnetic resonance imaging : JMRI.
[26] S. Sehlen,et al. The value of T1-weighted images in the differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE) , 2004, Neuroradiology.
[27] Ad Bax,et al. Improved solvent suppression in one-and two-dimensional NMR spectra by convolution of time-domain data , 1989 .
[28] F. Barkhof,et al. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[29] Remyelination in multiple sclerosis , 1979, Annals of neurology.
[30] O Henriksen,et al. In vivo quantitation of metabolite concentrations in the brain by means of proton MRS , 1995, NMR in biomedicine.
[31] B D Ross,et al. Absolute Quantitation of Water and Metabolites in the Human Brain. II. Metabolite Concentrations , 1993 .
[32] G J Barker,et al. The proton NMR spectrum in acute EAE: The significance of the change in the Cho:Cr ratio , 1993, Magnetic resonance in medicine.
[33] J H Simon,et al. A longitudinal study of T1 hypointense lesions in relapsing MS , 2000, Neurology.
[34] P M Matthews,et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques , 1992, Annals of neurology.
[35] V. Govindaraju,et al. Automated spectral analysis III: Application to in Vivo proton MR Spectroscopy and spectroscopic imaging , 1998, Magnetic resonance in medicine.
[36] T R Brown,et al. A fast, reliable, automatic shimming procedure using 1H chemical-shift-imaging spectroscopy. , 1995, Journal of magnetic resonance. Series B.
[37] F. Barkhof,et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.
[38] C. Lucchinetti,et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions , 2001, Annals of neurology.
[39] B J Soher,et al. Representation of strong baseline contributions in 1H MR spectra , 2001, Magnetic resonance in medicine.
[40] G. Fein,et al. Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.
[41] R. Grossman,et al. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. , 1995, AJNR. American journal of neuroradiology.
[42] Christopher M. Dobson,et al. Resolution enhancement of protein PMR spectra using the difference between a broadened and a normal spectrum , 1973 .
[43] P M Matthews,et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.
[44] B. Miller. A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and choline , 1991, NMR in biomedicine.
[45] R I Grossman,et al. Characterization of multiple sclerosis plaques with T1-weighted MR and quantitative magnetization transfer. , 1995, AJNR. American journal of neuroradiology.